Researchers are working to visualize and predict immune reconstitution syndrome (IRIS) in people with HIV in a new way -- with positron emission tomography (PET).
For the first time, scientists have shown that in certain people living with HIV, a type of antibody called immunoglobulin G3 (IgG3) stops the immune system's B cells from doing their normal job of fighting pathogens.
Prevalence of non-AIDS comorbidities prior to HIV diagnosis; wealth and HIV treatment access amidst universal health care; the uncertain benefits of food supplementation; the results of universal hepatitis C treatment access.
Tobacco use and HIV discrimination; enhancing viral suppression after prison with naltrexone; asymptomatic myocardial impairment during acute HIV infection; undetectability and yellow fever vaccine efficacy.
Researchers tested a single injection of the antibody canakinumab in HIV-positive people taking antiretroviral therapy and found that the drug significantly reduced inflammation and did not cause harm, at least in the short term.
Researchers found that inflammation in the arteries of HIV-positive people was "modestly increased" and that the level of inflammation in the lymph nodes was generally higher than in the arteries.
Researchers have found that having an elevated level of a protein that is released into the blood of people during chronic inflammation was linked to an increased risk for subsequent serious health problems as well as diminished survival.
Chronic HIV infection is associated with relatively high levels of inflammation and a growing body of evidence suggests that inflammation may increase the risk for a range of health problems.
A small study has found that HIV-positive men who used marijuana had fewer markers for HIV-associated inflammation than HIV-positive men who did not.
New research assesses the impact of chronic inflammation on major clinical events -- heart attack, stroke, cancer, other serious complications, and the risk of death.